Literature DB >> 8832876

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

J R Bischoff1, D H Kirn, A Williams, C Heise, S Horn, M Muna, L Ng, J A Nye, A Sampson-Johannes, A Fattaey, F McCormick.   

Abstract

The human adenovirus E1B gene encodes a 55-kilodalton protein that inactivates the cellular tumor suppressor protein p53. Here it is shown that a mutant adenovirus that does not express this viral protein can replicate in and lyse p53-deficient human tumor cells but not cells with functional p53. Ectopic expression of the 55-kilodalton EIB protein in the latter cells rendered them sensitive to infection with the mutant virus. Injection of the mutant virus into p53-deficient human cervical carcinomas grown in nude mice caused a significant reduction in tumor size and caused complete regression of 60 percent of the tumors. These data raise the possibility that mutant adenoviruses can be used to treat certain human tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8832876     DOI: 10.1126/science.274.5286.373

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  385 in total

1.  p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication.

Authors:  J N Harada; A J Berk
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Roles for the E4 orf6, orf3, and E1B 55-kilodalton proteins in cell cycle-independent adenovirus replication.

Authors:  F D Goodrum; D A Ornelles
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 3.  Apoptosis and cancer drug targeting.

Authors:  W R Sellers; D E Fisher
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 4.  Replication-selective adenoviruses as oncolytic agents.

Authors:  C Heise; D H Kirn
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 5.  Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

Authors:  T Hermiston
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

6.  Corepressor required for adenovirus E1B 55,000-molecular-weight protein repression of basal transcription.

Authors:  M E Martin; A J Berk
Journal:  Mol Cell Biol       Date:  1999-05       Impact factor: 4.272

7.  Effects of mutations in the adenoviral E1B 55-kilodalton protein coding sequence on viral late mRNA metabolism.

Authors:  Ramon A Gonzalez; S J Flint
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 8.  Gene therapy for prostate cancer.

Authors:  J R Gingrich; R D Chauhan; M S Steiner
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 9.  Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

Authors:  B R Dix; S J Edwards; A W Braithwaite
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

10.  Adenovirus vectors with the 100K gene deleted and their potential for multiple gene therapy applications.

Authors:  B L Hodges; H K Evans; R S Everett; E Y Ding; D Serra; A Amalfitano
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.